Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04618211 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
A Phase 2 study, sponsored by Pharvaris Netherlands B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT04618211 is a Phase 2 study that has completed, run by Pharvaris Netherlands B.V.. The registered enrollment target is 74 participants.
The verdict
NCT04618211, a Phase 2 study, has completed, sponsored by Pharvaris Netherlands B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of three single doses of deucrictibant and placebo. The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of deucrictibant with placebo.
Interventions
- DRUG Placebo
- DRUG Deucrictibant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2023-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04618211
The ClinicalTrials.gov registry entry for NCT04618211 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharvaris Netherlands B.V., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04618211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04618211 about?
NCT04618211 is a clinical study titled "Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema". This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of three single doses of deucrictibant and placebo. The study will compare symptom relief (skin pain, skin s...
What is the current status of trial NCT04618211?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2021-02-03. Estimated completion is 2023-03-01.
What interventions are being tested in trial NCT04618211?
The interventions under investigation include: Placebo (DRUG), Deucrictibant (DRUG).
Who is sponsoring clinical trial NCT04618211?
This trial is sponsored by Pharvaris Netherlands B.V., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.